Kolexia
Dubot Coraline Gynécologie
Dubot Coraline
Gynécologie
Centre François-Baclesse
Caen, France
139 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Tumeurs du col de l'utérus Carcinomes Carcinome épithélial de l'ovaire Récidive tumorale locale Métastase tumorale Cellules tumorales circulantes Carcinome épidermoïde

Collaborateurs

Voir plus
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Bieche Ivan
Bieche Ivan
Institut Curie, Saint-Cloud, France

Industries

Voir plus
MSD
8 collaboration(s)
Dernière en 2023
Lilly
3 collaboration(s)
Dernière en 2023
OVERCOME
1 collaboration(s)
Dernière en 2020
GSK
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Age and ageing   14 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826): A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Essai Clinique (Merck & Co.)   12 janvier 2024
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
JAMA oncology   14 décembre 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   01 novembre 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Annals of oncology : official journal of the European Society for Medical Oncology   04 octobre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé.
Bulletin du cancer   12 août 2023